2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 417

Patient Reported Outcomes Pre and Post Intervention in Older Veterans with Chronic Back Pain
Abstract Number: 1391

Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Abstract Number: 2687

Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Abstract Number: 1722

Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Abstract Number: 1928

Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis
Abstract Number: 1434

Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome
Abstract Number: 2549

Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Abstract Number: 870

Patient-Reported Burden of Gout in 2017 from the United States
Abstract Number: 723

Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Abstract Number: 2480

Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Abstract Number: 2911

Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Abstract Number: 2651

Patients Characteristics and Patters of Treatment in Refractory Systemic Lupus Erythematosus Patients in the Pre-Biologic Period: Data from a Multiethnic, Multinational Latin American Lupus Cohort
Abstract Number: 2369

Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Abstract Number: 384

Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
Abstract Number: 2030

Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].